164 related articles for article (PubMed ID: 31606972)
1. Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis.
Fattahi M; Eskandari N; Sotoodehnejadnematalahi F; Shaygannejad V; Kazemi M
Cell J; 2020 Apr; 22(1):92-95. PubMed ID: 31606972
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
Fattahi M; Rezaei N; Nematalahi FS; Shaygannejad V; Fouladi S; Karimi L; Fathi F; Dehghani L; Mirmosayyeb O; Eskandari N
Mult Scler Relat Disord; 2019 Oct; 35():241-245. PubMed ID: 31421628
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta.
Karimi L; Eskandari N; Shaygannejad V; Zare N; Andalib A; Khanahmad H; Mirmosayyeb O
Iran J Allergy Asthma Immunol; 2020 Aug; 19(4):416-425. PubMed ID: 33463108
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Interferon-Beta Therapy on T-Helper 17/miR-326 and T-Helper 1/miR-29b-3p Axis in Relapsing-Remitting Multiple Sclerosis Patients.
Karimi L; Eskandari N; Shaygannejad V
Neuroimmunomodulation; 2022; 29(3):177-185. PubMed ID: 34808619
[TBL] [Abstract][Full Text] [Related]
5. Connection of miR-185 and miR-320a expression levels with response to interferon-beta in multiple sclerosis patients.
Mousavi SR; Tahmasebivand M; Khorrami M; Ayromlou H; Khalili SK; Khorvash F; Rikhtegar R; Khademi B; Bahmanpour Z; Emamalizadeh B
Mult Scler Relat Disord; 2020 Sep; 44():102264. PubMed ID: 32554287
[TBL] [Abstract][Full Text] [Related]
6. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.
Honardoost MA; Kiani-Esfahani A; Ghaedi K; Etemadifar M; Salehi M
Gene; 2014 Jul; 544(2):128-33. PubMed ID: 24792898
[TBL] [Abstract][Full Text] [Related]
7. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis.
Ahmadian-Elmi M; Bidmeshki Pour A; Naghavian R; Ghaedi K; Tanhaei S; Izadi T; Nasr-Esfahani MH
Immunogenetics; 2016 Jan; 68(1):43-54. PubMed ID: 26563334
[TBL] [Abstract][Full Text] [Related]
8. Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β.
De Felice B; Mondola P; Sasso A; Orefice G; Bresciamorra V; Vacca G; Biffali E; Borra M; Pannone R
BMC Med Genomics; 2014 May; 7():26. PubMed ID: 24885345
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.
Hecker M; Thamilarasan M; Koczan D; Schröder I; Flechtner K; Freiesleben S; Füllen G; Thiesen HJ; Zettl UK
Int J Mol Sci; 2013 Aug; 14(8):16087-110. PubMed ID: 23921681
[TBL] [Abstract][Full Text] [Related]
10. miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients.
Ehtesham N; Khorvash F; Kheirollahi M
J Mol Neurosci; 2017 Jan; 61(1):16-24. PubMed ID: 27752929
[TBL] [Abstract][Full Text] [Related]
11. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of mir-301a in PBMCs of patients with relapsing-remitting multiple sclerosis is associated with reduced NKRF and PIAS3 expression levels and disease activity.
Tavakolpour V; Shokri G; Naser Moghadasi A; Mozafari Nahavandi P; Hashemi M; Kouhkan F
J Neuroimmunol; 2018 Dec; 325():79-86. PubMed ID: 30316680
[TBL] [Abstract][Full Text] [Related]
13. miR-141 and miR-200a, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis.
Naghavian R; Ghaedi K; Kiani-Esfahani A; Ganjalikhani-Hakemi M; Etemadifar M; Nasr-Esfahani MH
PLoS One; 2015; 10(5):e0124555. PubMed ID: 25938517
[TBL] [Abstract][Full Text] [Related]
14. B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis.
Tacke S; Braune S; Rovituso DM; Ziemssen T; Lehmann PV; Dikow H; Bergmann A; Kuerten S
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33707177
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients.
Ghadiri N; Emamnia N; Ganjalikhani-Hakemi M; Ghaedi K; Etemadifar M; Salehi M; Shirzad H; Nasr-Esfahani MH
Gene; 2018 Jun; 659():109-117. PubMed ID: 29551498
[TBL] [Abstract][Full Text] [Related]
16. Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.
Aliaga-Gaspar P; Hurtado-Guerrero I; Ciano-Petersen NL; Urbaneja P; Brichette-Mieg I; Reyes V; Rodriguez-Bada JL; Alvarez-Lafuente R; Arroyo R; Quintana E; Ramió-Torrentà L; Alonso A; Leyva L; Fernández O; Oliver-Martos B
Front Immunol; 2021; 12():778204. PubMed ID: 34975865
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of CD4+T-Cell Derived MiR-223 in The Relapsing Phase of Multiple Sclerosis Patients.
Hosseini A; Ghaedi K; Tanhaei S; Ganjalikhani-Hakemi M; Teimuri S; Etemadifar M; Nasr Esfahani MH
Cell J; 2016; 18(3):371-80. PubMed ID: 27602319
[TBL] [Abstract][Full Text] [Related]
18. miR-155 and functional proteins of CD8+ T cells as potential prognostic biomarkers for relapsing-remitting multiple sclerosis.
Elkhodiry AA; Zamzam DA; El Tayebi HM
Mult Scler Relat Disord; 2021 Aug; 53():103078. PubMed ID: 34171684
[TBL] [Abstract][Full Text] [Related]
19. Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients.
Arisi I; Malimpensa L; Manzini V; Brandi R; Gosetti di Sturmeck T; D'Amelio C; Crisafulli S; Ferrazzano G; Belvisi D; Malerba F; Florio R; Pascale E; Soreq H; Salvetti M; Cattaneo A; D'Onofrio M; Conte A
Front Immunol; 2023; 14():1234869. PubMed ID: 38152407
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
Gurevich M; Miron G; Falb RZ; Magalashvili D; Dolev M; Stern Y; Achiron A
BMC Neurol; 2015 Nov; 15():240. PubMed ID: 26589141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
